Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update

Author(s): Stephan Kruck, Markus A. Kuczyk, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl, Axel S. Merseburger

Journal Name: Reviews on Recent Clinical Trials

Volume 3 , Issue 3 , 2008

Become EABM
Become Reviewer
Call for Editor


Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [212 - 216]
Pages: 5
DOI: 10.2174/157488708785700311
Price: $65

Article Metrics

PDF: 3